Baird Financial Group, Inc. Seagen Inc. Transaction History

Baird Financial Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $332,652 - $375,469	-1,737 Reduced 6.69%	24,222 $5.14 Million
Q2 2023 Aug 11, 2023	BUY	$187.64 - $206.25 $198,710 - $218,418	1,059 Added 4.25%	25,959 $5 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $223,665 - $355,999	1,753 Added 7.57%	24,900 $5.04 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $177,338 - $236,124	1,311 Added 6.16%	22,582 $3.09 Million
Q2 2022 Aug 08, 2022	BUY	$108.81 - $179.33 $31,990 - $52,723	294 Added 1.4%	21,271 $3.76 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $9,808 - $12,943	82 Added 0.39%	20,977 $3.02 Million
Q4 2021 Feb 09, 2022	SELL	$142.57 - $190.86 $1.09 Million - $1.46 Million	-7,675 Reduced 26.86%	20,895 $3.23 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $51,709 - $61,644	363 Added 1.29%	28,570 $4.85 Million
Q2 2021 Aug 11, 2021	BUY	$135.08 - $161.1 $1.06 Million - $1.27 Million	7,863 Added 38.65%	28,207 $4.45 Million
Q1 2021 May 13, 2021	BUY	$137.51 - $190.8 $12,788 - $17,744	93 Added 0.46%	20,344 $2.83 Million
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $3.33 Million - $4.29 Million	20,251 New	20,251 $3.55 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.